BNB Plus Corp Dossier
|
SectorHealth Care IndustryLife Sciences Tools & Services Beta (adjusted)0.68 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $0.14Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $889.3K Enterprise Value −$59.8K Shares Outstanding 6.2M diluted All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary BNB Plus Corp. (formerly Applied DNA Sciences, Inc.) has undergone a dramatic strategic pivot from a pure-play biotechnology firm to a Digital Asset Treasury (DAT) company focused on accumulating and generating yield from BNB, the native token of the Binance ecosystem. While its biotech subsidiary, LineaRx, achieved profitability in Q2 FY2026 and recently completed its largest-ever $1.2 million LineaDNA order, the company's core valuation is now heavily tied to its $12.2 million BNB treasury and its active yield-generation strategies. A formal strategic review is underway to evaluate pathways for maximizing shareholder value, including the potential monetization of LineaRx and expansion into digital asset/AI infrastructure. Given the high volatility of digital assets, regulatory uncertainties surrounding BNB, and the ongoing strategic transition, a Hold recommendation is warranted until there is clearer execution on the strategic alternatives. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario Regulatory crackdowns on the Binance ecosystem or BNB token severely depress the value of the treasury. Additionally, the strategic review fails to monetize LineaRx on favorable terms, forcing the company to continue funding biotech R&D through dilutive equity or preferred stock financing, eroding shareholder value. Base CaseCentral scenario The company successfully maintains its BNB treasury yield strategies, compounding its holdings while stabilizing its cash burn. LineaRx is either spun off or licensed, providing non-dilutive capital to fund the DAT expansion. The stock trades in line with its net asset value (NAV) and the underlying price of BNB. Bull CaseUpside scenario The bull case hinges on the successful execution of the BNB yield-generation strategy, compounding treasury holdings to increase BNB per share, alongside the potential high-value monetization or licensing of the profitable LineaRx biotechnology subsidiary. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |